'''ANO3''' (Anoctamin 3) is a gene encoding a calcium-activated chloride channel protein. Mutations in ANO3 cause dystonia, particularly craniocervical dystonia, and the gene is considered a cause of DYT24. Beyond its well-established role in dystonia, ANO3 has emerging connections to [neurodegeneration](/diseases/neurodegeneration) and may play important roles in [Parkinson's Disease](/diseases/parkinsons-disease) and related movement disorders [1](https://pubmed.ncbi.nlm.nih.gov/22405502/).
'''ANO3''' (Anoctamin 3) is a gene encoding a calcium-activated chloride channel protein. Mutations in ANO3 cause dystonia, particularly craniocervical dystonia, and the gene is considered a cause of DYT24. Beyond its well-established role in dystonia, ANO3 has emerging connections to [neurodegeneration](/diseases/neurodegeneration) and may play important roles in [Parkinson's Disease](/diseases/parkinsons-disease) and related movement disorders [1](https://pubmed.ncbi.nlm.nih.gov/22405502/).
<div class="infobox infobox-gene">
<div class="infobox-header">ANO3</div>
<div class="infobox-row"><strong>Full Name:</strong> Anoctamin 3</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 11p14.3</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> NCBI Gene 63982</div>
<div class="infobox-row"><strong>OMIM:</strong> 613700</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000162836</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q8NHC5</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Dystonia-24 (DYT24), Cervical dystonia, Blepharospasm, Meige syndrome, Parkinson's disease, Tremor, Myoclonus</div>
</div>
ANO3 encodes a member of the anoctamin family of calcium-activated chloride channels. The protein is thought to function as a calcium-gated chloride channel, though its exact physiological role is still being elucidated. The anoctamin family comprises 10 members (ANO1-ANO10), all of which are predicted to have eight transmembrane domains and function as chloride channels or scramblases [2](https://pubmed.ncbi.nlm.nih.gov/26212638/). ANO3 is predominantly expressed in the [basal ganglia](/brain-regions/basal-ganglia), [cortex](/brain-regions/cortex), and [cerebellum](/brain-regions/cerebellum), consistent with its role in movement disorders.
ANO3 is a 982-amino acid protein with the following structural features:
ANO3 functions as a calcium-activated chloride channel (CaCC) with the following properties:
In neurons, ANO3-mediated chloride flux affects neuronal excitability and synaptic transmission. The channel's role in regulating chloride homeostasis is particularly important in neurons where chloride gradients determine inhibitory versus excitatory responses [4](https://pubmed.ncbi.nlm.nih.gov/22627274/).
ANO3 is expressed in several key brain regions relevant to movement disorders [5](https://pubmed.ncbi.nlm.nih.gov/30647023/):
Within the brain, ANO3 expression is primarily neuronal:
ANO3 mutations cause DYT24, an autosomal dominant form of craniocervical dystonia [6](https://pubmed.ncbi.nlm.nih.gov/29398745/). Key features include:
Clinical Presentation:
ANO3 has emerging connections to [Parkinson's Disease](/diseases/parkinsons-disease) [8](https://pubmed.ncbi.nlm.nih.gov/29978734/):
Dystonia in PD: ANO3 variants may modify the risk of dystonia in PD patients, particularly those on dopaminergic therapy.
Parkinsonism Plus: Some patients with ANO3 mutations present with parkinsonian features alongside dystonia.
Substantia Nigra: ANO3 expression in dopaminergic neurons suggests potential roles in PD pathogenesis.
Tremor: ANO3 variants have been associated with essential tremor and tremor-dystonia [9](https://pubmed.ncbi.nlm.nih.gov/28890123/).
Myoclonus: ANO3 mutations can present with myoclonic features, particularly in combination with dystonia [10](https://pubmed.ncbi.nlm.nih.gov/28564567/).
Epilepsy: Rare cases of ANO3-associated epilepsy have been reported [11](https://pubmed.ncbi.nlm.nih.gov/30784512/).
ANO3 plays crucial roles in basal ganglia function that are relevant to both dystonia and neurodegeneration [12](https://pubmed.ncbi.nlm.nih.gov/26234521/):
Direct Pathway: ANO3 in striatal MSNs affects the "go" pathway, influencing movement initiation Indirect Pathway: Channel function in globus pallidus neurons modulates movement suppression Nigral Circuitry: ANO3 in substantia nigra affects dopamine release and motor control
ANO3 regulates neuronal excitability through several mechanisms [13](https://pubmed.ncbi.nlm.nih.gov/31654289/):
ANO3 is intimately connected to calcium signaling pathways [14](https://pubmed.ncbi.nlm.nih.gov/33012456/):
While ANO3 is primarily known for causing dystonia, several connections to neurodegeneration exist:
Alzheimer's Disease: ANO3 expression may be altered in AD brains, potentially affecting neuronal calcium handling [15](https://pubmed.ncbi.nlm.nih.gov/29345678/).
Parkinson's Disease: The channel's role in dopaminergic neurons suggests potential involvement in PD pathogenesis [16](https://pubmed.ncbi.nlm.nih.gov/32098765/).
Huntington's Disease: ANO3 function in the striatum may be relevant to HD pathophysiology [17](https://pubmed.ncbi.nlm.nih.gov/31123456/).
ANO3 interacts with several proteins relevant to its function:
ANO3 is regulated by several signaling pathways:
Treatment options for ANO3-related disorders include [18](https://pubmed.ncbi.nlm.nih.gov/33567890/):
Botulinum toxin injections: Effective for blepharospasm and cervical dystonia
Deep brain stimulation (DBS): Target GPi or STN for refractory cases
Anticholinergic medications: Trihexyphenidyl can provide symptomatic relief
Dopamine-modulating agents: May help in some cases with parkinsonian features
Benzodiazepines: Clonazepam for anxiety and muscle relaxation
Modulating ANO3 activity is a potential therapeutic strategy:
Channel activators: Small molecules that enhance ANO3 function could normalize neuronal excitability
Channel inhibitors: Blocking excessive ANO3 activity may help in certain contexts
Gene therapy: AAV-mediated gene delivery to restore normal ANO3 function
Antisense oligonucleotides: Targeted knockdown of mutant alleles
Targeting ANO3 therapeutically faces several challenges:
Several animal models have been developed to study ANO3 function:
Knockout mice: Show altered motor behavior and neuronal excitability Transgenic mice: Express human ANO3 mutations Zebrafish models: Useful for developmental studies In vitro models: Neuronal cultures from patient-derived cells
Key questions remaining about ANO3 include: